TARGETED THERAPIES Afatinib-new therapy option for EGFR-mutant lung cancer

被引：81

作者：

Yu, Helena A. ^{[1
]}

Pao, William ^{[2
]}

机构：

[1] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv,Div Solid Tumor Oncol, New York, NY 10065 USA

[2] Vanderbilt Ingram Canc Ctr, Div Hematol Oncol, Nashville, TN 37212 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2013年 / 10卷 / 10期

关键词：

1ST-LINE TREATMENT; OPEN-LABEL; ERLOTINIB; CHEMOTHERAPY; MULTICENTER; PHASE-3; TRIAL;

D O I：

10.1038/nrclinonc.2013.154

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

On 15 July 2013, the FDA approved afatinib as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours harbour exon 19 deletions or exon 21 (L858R) EGFR substitution mutations. We discuss three recent studies investigating afatinib in this molecular subset of patients.

引用

页码：551 / 552

页数：2

共 50 条

[31] An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo
Koichi Tomoshige
Minzhe Guo
Tomoshi Tsuchiya
Takuya Fukazawa
Iris M. Fink-Baldauf
William D. Stuart
Yoshio Naomoto
Takeshi Nagayasu
Yutaka Maeda
Oncogene, 2018, 37 : 3894 - 3908
[32] Acquired Resistance to Afatinib in EGFR- Mutant Lung Cancer
Sequist, L. V.
Gerber, D. E.
Fidias, P.
Shaw, A. T.
Temel, J. S.
Heist, R. S.
Gainor, J. F.
Fulton, L.
Kennedy, E. A.
Muzikansky, A.
Engelma, J. A.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S43 - S44
[33] Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer
Wang, Shidan
Rong, Ruichen
Yang, Donghan M.
Fujimoto, Junya
Bishop, Justin A.
Yan, Shirley
Cai, Ling
Behrens, Carmen
Berry, Lynne D.
Wilhelm, Clare
Aisner, Dara
Sholl, Lynette
Johnson, Bruce E.
Kwiatkowski, David J.
Wistuba, Ignacio I.
Bunn, Paul A.
Minna, John
Xiao, Guanghu
Kris, Mark G.
Xie, Yang
JOURNAL OF CLINICAL INVESTIGATION, 2023, 133 (02):
[34] Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer
Shaurova, Tatiana
Zhang, Letian
Goodrich, David W.
Hershberger, Pamela A.
FRONTIERS IN GENETICS, 2020, 11
[35] Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
To, Kenneth K. W.
Fong, Winnie
Cho, William C. S.
FRONTIERS IN ONCOLOGY, 2021, 11
[36] EGFR-mutant lung cancer: what's new with respect to activity and resistance?
不详
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2018, 11 : S73 - S77
[37] ERBBal Remedies: Combination Therapy for EGFR-mutant Lung Cancers
Fan, Pang-Dian
Yu, Helena A.
CLINICAL CANCER RESEARCH, 2018, 24 (22) : 5499 - 5501
[38] Capmatinib and Osimertinib Combination Therapy for EGFR-Mutant Lung Adenocarcinoma
Gautschi, Oliver
Menon, Roopika
Bertrand, Miriam
Murer, Christian
Diebold, Joachim
JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (01) : E13 - E15
[39] Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study
Dongliang Bian
Liangdong Sun
Junjie Hu
Liang Duan
Haoran Xia
Xinsheng Zhu
Fenghuan Sun
Lele Zhang
Huansha Yu
Yicheng Xiong
Zhida Huang
Deping Zhao
Nan Song
Jie Yang
Xiao Bao
Wei Wu
Jie Huang
Wenxin He
Yuming Zhu
Gening Jiang
Peng Zhang
Nature Communications, 14
[40] Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer
Wu, Fang
Liu, Xianling
Ma, Jin-an
Gao, Yawen
Hu, Chunhong
LANCET ONCOLOGY, 2018, 19 (03): : E124 - E124

← 1 2 3 4 5 →